CorMedix faces Sept. 23 hearing on settlement of shareholder derivative lawsuits

Reuters2026/08/07 20:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CorMedix faces proposed settlements to end two shareholder derivative suits tied to alleged disclosure failures on DefenCath manufacturing issues in 2019-2022.
Settlement terms call for corporate governance reforms to be adopted or maintained for at least 3.5 years; no cash payments to shareholders.
U.S. District Judge Julien Xavier Neals set a Sept. 23, 2026 hearing in Newark to consider final approval under Rule 23.1.
Plaintiffs’ lawyers plan to seek up to USD 3.9 million in fees and expenses; defendants reserved the right to oppose.
Objections must be filed by Sept. 2, 2026 from holders of common stock as of Jan. 19, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410098-26-000044), on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CorMedix faces Sept. 23 hearing on settlement of shareholder derivative lawsuits

You may also like

Crypto prices